Kern Whelan Capital
VC Fund
San Francisco, United States
Kern Whelan Capital is a VC fund in San Francisco focused on Mobile and Software. Kern Whelan Capital manages a diversified investment portfolio stretching from new ventures to established and profitable businesses across many industry sectors. They invest in only a few companies each year, and partner with outstanding management teams for the long term. While they typically are active members of the board of directors for theirbusinesses, they do not seek involvement in their daily operations. Through a long term approach to the liquidity horizon, Kern Whelan investments are not beholden to a single exit strategy, but are instead opportunistic about investor capital return whether through M&A, IPO, recap, dividend, or otherwise.Investment ApproachThey back strong management teams in companies that generate, or have the potential to generate, operating profit margins of 15% or better. They look for a history of internal growth in a capital efficient manner with good prospects for future growth. They remain opportunistic investors, however, and will not rule out any opportunity with strong cash flow potential. They prefer simple capital structures so that their interests are more closely aligned with management. As Kern Whelan principals they demonstrate their commitment to the success of their investors, management and business by typically serving as the largest personal investors in each of their portfolio companies.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Kern Whelan Capital invests in
Stages Kern Whelan Capital invests in
Countries Kern Whelan Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jay Kern
|
|||
Investment Focus
Industry
- Mobile 1 (33%)
- Software 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series B 2 (67%)
- Series C 1 (33%)
Country
- Australia 1 (33%)
- United States 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jay Kern
Founder and General Partner
|
Founder and General Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GPN Vaccines
|
GPN Vaccines are a type of vaccine that is used to prevent the spread developing a vaccine against streptococcus pneumoniae. | $12M / Series B / Jun 06, 2024 | |
Quri
|
Quri is a retail intelligence company that provides instant visibility into the performance of products and promotions in retail stores. Quri enables brands and retailers to measure and optimize the exact shopper experience, maximizing in-store product revenue and profitability. Quri is powered by a nationwide, on-demand mobile field force ofsecret shoppers who can be immediately deployed to any retail location in the U.S., providing real-time actionable data and insights to brands and retailers. | $17M / Series C / Oct 14, 2015 | |
Cohera Medical
|
Cohera Medical is a medical device company that is actively developing a line of surgical adhesives and sealants. Its products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use and forms a strong bond between tissue layers. The company's lead product, TissuGlu® Surgical Adhesive, is indicated for use in theU.S. for the approximation of tissue planes in abdominoplasty procedures. TissuGlu is currently approved for sale in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty and is being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flaps surgical procedures such as abdominoplasty, mastectomy, lymph node dissection, decubitus, and latissimus dorsi flap procedures. Its second product under development, Sylys® Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, has received CE Mark approval in Europe as an adjunct to standard closure in ileostomy reversal procedures. TissuGlu and Sylys are the first products in a pipeline of technology that includes surgical mesh adhesives, hemostatic foam, bone adhesives, and drug delivery. Sylys and the other Cohera Medical products are currently available for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S. or in any other market. | Series B |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kern Whelan Capital invest in?
Kern Whelan Capital invests primarily in Mobile, Software and Biotechnology startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kern Whelan Capital?
Public channels for Kern Whelan Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kern Whelan Capital?
The team at Kern Whelan Capital includes Jay Kern (Founder and General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
